|
·
|
InterCure Ltd., a medical device company, is successfully selling the world’s first, FDA- |
|
·
|
InterCure’s broadly patented Device- |
|
·
|
Headquartered from Fort Lee, New Jersey and Lod Israel, InterCure is an Israeli private company founded in 1994 by Dr. Benjamin Gavish and Erez Gavish. InterCure also operates a marketing office in London, outsourced call centers/warehouses in NJ, Southampton, UK and Saskatchewan, Canada. Resperate Breath Control Blood Pressure Lowering Device itself is produced in Nazareth, Israel. |
|
·
|
InterCure's investors span three continents and include Nikko Capital and Nippon Venture Capital from Japan, Palladin Capital from the US and Medica Venture Partners, United Mizrahi Bank from Israel as well as its Israeli seed investors Yaacov Shachar and Arie Ovadia. |
|
·
|
90% of Resperate Breath Control Blood Pressure Lowering Device owners are satisfied with the device and are still using it regularly after eight to twelve weeks. |
|
·
|
Two- |
|
·
|
Already 20% of primary care physicians in the US are aware of Resperate Breath Control Blood Pressure Lowering Device. 6 out of 10 of these physicians recommend the product. |
|
·
|
90% of Resperate Breath Control Blood Pressure Lowering Device owners are over the age of 50 (equally male and female). |
|
·
|
Owners are health- |
|
·
|
2/3 of Resperate Breath Control Blood Pressure Lowering Device owners are on medications, most of whom suffer from side effects and almost all of whom have previously tried diet and exercise to lower their blood pressure. |